Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OB-002H Gel in Healthy Adults
NCT04791007Phase 1Completed
- Sponsor
- Orion Biotechnology
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OB-002 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Orion Biotechnology. Primary endpoint: Safety of OB-002H gel at 7 weeks. Started Oct 2019; status: completed.
02
Drugs
OB-002
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04791007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791007.